{"id":51668,"date":"2025-12-20T22:02:30","date_gmt":"2025-12-20T14:02:30","guid":{"rendered":"https:\/\/flcube.com\/?p=51668"},"modified":"2025-12-20T22:02:31","modified_gmt":"2025-12-20T14:02:31","slug":"leadingtac-raises-rmb-200m-series-b-to-advance-protein-degradation-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51668","title":{"rendered":"Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline"},"content":{"rendered":"\n

Leadingtac Pharmaceutical Co., Ltd.<\/strong> announced the successful completion of its Series B financing round<\/strong>, raising over RMB 200 million<\/strong> (\u2248\u202fUS$28\u202fmillion). The round was led by Hangkang Capital<\/strong>, with participation from CDH VGC, New Day Fund, and Kangcheng Capital<\/strong>. Existing shareholder Long Rock Capital<\/strong> also increased its investment. Proceeds will accelerate clinical development of its IRAK4 degrader (LT\u2011002)<\/strong> and KRAS G12D degrader<\/strong>, expand its Shaoxing R&D Center<\/strong>, and advance preclinical autoimmune and oncology pipelines.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Component<\/th>Details<\/th><\/tr><\/thead>
Financing Round<\/strong><\/td>Series B<\/td><\/tr>
Amount Raised<\/strong><\/td>Over RMB 200 million (\u2248\u202fUS$28\u202fmillion)<\/td><\/tr>
Lead Investor<\/strong><\/td>Hangkang Capital<\/td><\/tr>
Co\u2011Investors<\/strong><\/td>CDH VGC, New Day Fund, Kangcheng Capital<\/td><\/tr>
Existing Shareholder<\/strong><\/td>Long Rock Capital (increased stake)<\/td><\/tr>
Company Valuation<\/strong><\/td>Undisclosed<\/td><\/tr>
Use of Proceeds<\/strong><\/td>Clinical advancement, platform upgrade, R&D expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Use of Proceeds Breakdown<\/h2>\n\n\n\n
Priority<\/th>Details<\/th><\/tr><\/thead>
LT\u2011002 (IRAK4 Degrader)<\/strong><\/td>Accelerate Phase\u202fIc indication exploration and Phase\u202fII clinical studies<\/td><\/tr>
KRAS G12D Degrader<\/strong><\/td>Initiate Phase\u202fI clinical trials<\/td><\/tr>
Preclinical Pipeline<\/strong><\/td>Advance other autoimmune and oncology programs<\/td><\/tr>
Operational Support<\/strong><\/td>Full operation of Leading\u2011Top Shaoxing R&D Center and team expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Company Profile<\/h2>\n\n\n\n
Founded<\/th>Focus<\/th>Core Platform<\/th><\/tr><\/thead>
2019<\/strong><\/td>First\u2011in\u2011Class and Best\u2011in\u2011Class small molecule drugs<\/td>Targeted Protein Degradation (TPD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Therapeutic Areas:<\/strong> Autoimmune disorders and oncology<\/p>\n\n\n\n

Market Opportunity & Strategic Context<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
Protein Degradation Market<\/strong><\/td>$5\u20118\u202fbillion<\/strong> (global, 2025)<\/td>Growing at 25\u201130% CAGR<\/td><\/tr>
IRAK4 Target<\/strong><\/td>Key node in TLR\/IL\u20111R inflammatory pathways<\/td>High interest for autoimmune diseases<\/td><\/tr>
KRAS G12D Market<\/strong><\/td>$2\u20113\u202fbillion<\/strong> potential (oncology)<\/td>Undruggable target until recently; degraders show promise<\/td><\/tr>
TPD Platform Value<\/strong><\/td>Multiple shots on goal<\/strong> reduces risk<\/td>Validates degrader modality across disease areas<\/td><\/tr>
Peak Sales Potential<\/strong><\/td>\u00a53\u20115\u202fbillion<\/strong> (\u2248\u202fUS$420\u2011700\u202fM) by 2032<\/td>Assuming 2\u20113 approved products<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n